Lithium treatment and potential long-term side effects: A systematic review of the literature;Trattamento con litio e potenziali effetti collaterali a lungo termine: Una revisione sistematica della letteratura

Rivista di Psichiatria

Volumn 49, Issue 1, 2014, Pages 12-21

  Albert, Umberto ^a   De Cori, David ^a   Blengino, Giovanni ^a   Bogetto, Filippo ^a   Maina, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bipolar disorder; Lithium; Long term; Side effects

Indexed keywords

CALCIUM; LITHIUM; PARATHYROID HORMONE; THYROTROPIN; LITHIUM CARBONATE; TRANQUILIZER;

CALCIUM BLOOD LEVEL; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHYROIDISM; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; LONG TERM CARE; MEDLINE; NEPHROGENIC DIABETES INSIPIDUS; PARATHYROID HORMONE BLOOD LEVEL; POLYDIPSIA; POLYURIA; PSORIASIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; THYROTROPIN BLOOD LEVEL; URINARY TRACT DISEASE; BIPOLAR DISORDER; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG ERUPTIONS; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY DISEASE; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIMANIC AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DRUG ERUPTIONS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOTHYROIDISM; KIDNEY DISEASES; LITHIUM CARBONATE; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROTROPIN;

EID: 84896266165     PISSN: 00356484     EISSN: 20382502     Source Type: Journal    
DOI: 10.1708/1407.15620     Document Type: Review

References (81)

1. Cade JFJ. Lithium salt in the treatment of psychotic excitement. Med J Aust 1949; 36: 349-52.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
3. National Institute for Health and Clinical Excellence (NICE). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: National Institute for Health and Clinical Excellence, 2006.
4. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-88.
5. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5: 120-35. (Pubitemid 44121706)
6. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10: 85-116.
7. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15: 1-44.
8. Licht RS. Lithium: still a major option in the management of bipolar disorder. CNS Neuroscience & Therapeutics 2012; 18: 219-26.
9. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-19. (Pubitemid 41428610)
10. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Geddes GR. Decreased risk of suicides and attemps during long-term lithium treatment: a meta-analytic review. Bipolar Disorder 2006; 8: 625-39. (Pubitemid 44567144)
11. Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry 2012; 46: 192-211.
12. McKnight RF, Adida M, Budge K, Stockon S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-8.
13. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Safety 1999; 21: 449-56. (Pubitemid 30021101)
14. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5: 270-6.
15. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10: 329-45. (Pubitemid 17161686)
16. Grandjean ME, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part II: Clinical Pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331-49.
17. Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand 2012; 126: 186-97.
18. Paul R, Minay J, Cardwell C, Fogart D, Kelly C. Meta-analysis of the effects of lithium usage on serum creatinine levels. J Psychopharmacol 2010; 24: 1425-31.
19. Bendz H, Schon S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77: 219-24.
20. Coresh J, Astor B, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
21. Adam WR, Sshweittzer I, Walker RG. Trade-off between the benefits of lithium treatment and the risk of chronic kidney disease. Nephrology 2012; 17: 776-9.
22. Hestbech J, Aurell M. Lithium-induced uraemia. Lancet 1979; 1: 212-3. (Pubitemid 9095591)
23. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controller, prospective lithium-withdrawal study. Nephrol Dial Transplant 1996; 11: 457-60. (Pubitemid 26093740)
24. Presne C, Fakhouri F, Noel LH, et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 2003; 64: 585-92. (Pubitemid 36871930)
25. Markowitz GS, Radhakrishnan J, Kambhan N, Valeri AM, Hines WH, Diagati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11: 1439-48. (Pubitemid 30483460)
26. Bassilios N, Martel P, Godard V, et al. Monitoring of glomerular filtration rate in lithium-treated outpatients-an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008; 23: 562-5. (Pubitemid 351767609)
27. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-39. (Pubitemid 44824712)
28. Ng F, Oomen KM, Wilting I, et al. The International Society for Bipolar Disorder (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11: 559-95.
29. Morriss R, Benjamin B. Lithium and eGFR: a new routinely available tool for the prevention of chronic kidney disease. Br J Psychiatry 2008; 193: 93-5.
30. Kripalani M, Shawcross J, Reilly J, Main J. Lithium and chronic kidney disease. BMJ 2009; 3: 339:b2452. doi: 10.1136/bmj.b2452.
31. Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Research 2013; 6: 3.
32. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2006; 2: 23.
33. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007; 30: 363-6. (Pubitemid 47098230)
34. Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry 1999; 175: 336-9. (Pubitemid 29470863)
35. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68.
36. Chakrabarti S. Thyroid functions and bipolar affective disorder. J Thyroid Res 2011; 2011:306367. doi: 10.4061/2011/306367.
37. Vincent A, Baruch P, Vincent P. Early onset of lithium-associated hypothyroidism. J Psychiatry Neurosci 1993; 18: 74-7.
38. Berens SC, Bernstei RS, Robbins J, Wolf J. Antithyroid effects of lithium. J Clin Invest 1970; 49: 1357-67.
39. Burrow GN, Burke WR, Himmelho JM, Spencer RP, Hershman JM. Effect of lithium on thyroid function. J Clin Endocrinol Metab 1971; 32: 647-52.
40. Lazarus J. Lihtium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 723-33.
41. Lazarus J. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8: 909-13. (Pubitemid 28514183)
42. Silverstone T. Is lithium still the maintenance treatment of choice for bipolar disorder? CNS Drugs 2000; 14: 81-94.
43. Frye MA, Yatham L, Ketter TA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand 2009; 120: 10-3.
44. Freeman MP, Freeman SA. Lithium: clinical consideration in internal medicine. Am J Med 2006; 119: 478-81. (Pubitemid 43795184)
45. Souza FGM, Mander AJ, Foggo M, Dick H, Shearing CH, Goodwin GM. The effects of lithium discontinuation and the non-effect or oral inositol upon thyroid-hormones and cortisol in patients with bipolar disorder. J Affect Dis 1991; 22: 165-70.
46. Schou M, Amdisen A, Eskjaer J, Jensen S, Olsen T. Occurrence of goiter during lithium treatment. Br Med J 1968; 21: 710-3.
47. Bocchetta A, Mossa P, Velluzzi F, Mariotti S, Del Zompo M, Loviselli A. A ten-year follow-up of thyroid function in lithium patients. J Clin Psychopharmacol 2001; 21: 594-8. (Pubitemid 33116659)
48. Rosser R. Thyrotoxicosis and lithium. Br J Psychiatry 1976; 128: 61-6.
49. Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol 1994; 40: 759-64. (Pubitemid 24216625)
50. Kirov G. Thyroid disorders in lithium-treated patients. J Affect Disord 1998; 50: 33-40. (Pubitemid 28338302)
51. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005; 87: 313-7. (Pubitemid 41039954)
52. Bandyopadhyay D, Nielsen C. Lithium-induced hyperthyroidism, thyrotoxicosis and mania: a case report. Q J Med 2012; 105:83-85.
53. Bendz H, Sjodin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240: 357-65.
54. Christensson T, Hellstrom K, Wengle B, Alveryd A, Wikland B. Prevalence of hypercalcemia in a health screening in Stockholm. Acta Med Scand 1976; 200: 131-7.
55. Nordenstrom J, Elvius M, Bagedahl-Strindlund M, Zhao B, Torring O. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism 1994; 43: 1563-7. (Pubitemid 24382709)
56. Kallner G, Petterson V. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years. Acta Psychiatr Scand 1995; 91: 48-51.
57. Seely EW, Moore TJ, LeBoff MS, Brown EM. A single dose of lithium carbonate acutely elevates intact parathyroid hormone levels in humans. Acta Endocrinol 1989; 121: 174-6. (Pubitemid 19212158)
58. Saunders BD, Saunders EFH, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 2009; 33: 2314-23.
59. Shen FH, Sherrard DJ. Lithium-induced hyperparathyroidism: an alteration of the "set-point". Ann Intern Med 1982; 96: 63-5.
60. Mak TWL, Shek CC, Chow CC, Wing YK, Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83: 3857-9. (Pubitemid 28513562)
61. Toffaletti J. Increase in dialyzable calcium associated with therapy with lithium 1979; 25: 1806-9.
62. Palmer M, Jakobsson S, Akerstrom G, Ljunghall S. Prevalence of hypercalcaemia in a health survey; a 14-year follow-up study of serum calcium values. Europ J Clin Invest 1988; 18: 39-46.
63. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 2009; 160: 317-23.
64. Endres DB. Investigation of hypercalcemia. Clinical Biochemistry 2012; 45: 954-63.
65. Wolf ME, Moffat M, Mosnaim J, Dempsey S. Lithium therapy, hypercalcemia, and hyperparathyroidism. Am J Ther 1997; 4: 323-5. (Pubitemid 27415267)
66. Palmer M, Bergstrom R, Akerstrom G, et al. Survival and renal function in untreated hypercalcemia population-based cohort study with 14 years of follow-up. Lancet 1987; 1: 59-62. (Pubitemid 17015771)
67. Khandwala HM, Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12: 54-8.
68. Vestergaard P, Amdisen A, Schou M. Clinically significant side-effects of lithium treatment: a survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62: 193-200. (Pubitemid 10010939)
69. Chan HL, Wing Y, Su R, Van Krevel C, Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000; 57: 107-13. (Pubitemid 30119963)
70. Sarantidis D, Waters BA. A review and controlled-study of cutaneous conditions associated with lithium-carbonate. Br J Psychiatry 1983; 143: 42-50. (Pubitemid 13057763)
71. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-41.
72. Yeung CK, Chan HHL. Cutaneous side effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3-8. (Pubitemid 38316537)
73. McCreadie RG, Morrison DP. The impact of lithium in Southwest Scotland. I. Demographic and clinical findings. Br J Psychiatry 1985; 146: 70-4. (Pubitemid 15153342)
74. Bowden CL, Calabrese JR, McElroy SL, et al. for the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-9. (Pubitemid 30257262)
75. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-61. (Pubitemid 41598271)
76. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Infiamm Allergy 2004; 3: 121-8. (Pubitemid 38832741)
77. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-7. (Pubitemid 32842766)
78. Brauchli YB, Jick SS, Curtin F, Meier CR. Lithium, antispychotics, and risk of psoriasis. J Clin Psychopharmacol 2009; 29: 134-40.
79. Basavaraj KH, Navya NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010; 49: 1351-61.
80. Jafferany M. Lithium and psoriasis: what primary care and family phisicians should know. Prim Care Companion J Clin Psychiatry 2008; 10: 435-9.
81. Hampton PJ, Jans R, Flockhart RJ, Parker G, Reynolds NJ. Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (Nuclear Factor of Activated T Cells 2). J Cell Physiol 2012; 227: 1529-37.